Trial reportAlimentary pharmacology & therapeutics2008
Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.
Trial report in Alimentary pharmacology & therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 28 citations in OpenAlex.
- CoexpressedMolecular pharmacology · 2024Article
- Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.The Journal of clinical investigation · 2013Review
- Current management strategies and emerging treatments for functional dyspepsia.Nature reviews. Gastroenterology & hepatology · 2013Review
- The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review.Middle East journal of digestive diseases · 2013Review
- Review article: current treatment options and management of functional dyspepsia.Alimentary pharmacology & therapeutics · 2012Review
- Current management of functional dyspepsia: impact of Rome III subdivision.Annals of gastroenterology · 2012Review
- Different faces of gastroparesis.World journal of gastroenterology · 2009Article
- Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.Neurogastroenterology and motility · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAsimadoline, a kappa-opioid agonist, reduces visceral sensitivity in experimental animal models and may decrease satiation and postprandial fullness in healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored.
aimTo evaluate the effects of asimadoline on satiation volume and postchallenge symptoms in functional dyspepsia.
methodsA randomized, double-blind trial evaluated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n = 13) or 1.0 mg (n = 13) or placebo (n = 14) b.d. in patients with functional dyspepsia (Rome II). Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index were used to assess symptoms during the 8-week treatment.
resultsOver 8 weeks of treatment, asimadoline had no significant effect on maximum-tolerated volume or aggregate symptom score with nutrient drink challenge, and on the mean of the total daily symptom severity score compared to placebo. In a post hoc analysis, asimadoline 0.5 mg significantly increased the maximum-tolerated volume (1217 mL +/- 90.2) compared to placebo (807 mL +/- 111.8) in patients with higher postprandial fullness scores (P = 0.01).
conclusionAsimadoline overall did not significantly alter maximum-tolerated volume, symptoms postnutrient challenge or symptoms over 8 weeks in functional dyspepsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.